Literature DB >> 17190768

Changes over a 20-year period in the clinical presentation of primary sclerosing cholangitis in Sweden.

Annika Bergquist1, Karouk Said, Ulrika Broomé.   

Abstract

OBJECTIVE: The use of magnetic resonance cholangiopancreaticography (MRCP) as a non-invasive diagnostic tool for primary sclerosing cholangitis (PSC), together with increased clinical awareness of the disease, has led to earlier diagnosis. The aim of this study was to investigate the clinical presentation of PSC including its association with inflammatory bowel disease (IBD) and the development of cholangiocarcinoma at one centre over an observation period of 20 years.
MATERIAL AND METHODS: All patients with well-defined PSC, diagnosed after 16 years of age and treated at Huddinge University Hospital between 1984 and 2004, were included in the study (n=246). PSC and IBD characteristics were retrieved from the patients' medical records. The patients were subdivided according to the date of diagnosis: 185 PSC patients diagnosed before 30 October 1998 were compared with 61 patients diagnosed after that date.
RESULTS: Patients diagnosed after 1998 were significantly older at diagnosis (mean age 41 versus 37 years) and presented fewer symptoms (47% versus 63%) as well as a lower frequency of coexisting IBD (69% versus 82%). In the whole group, women had significantly more symptoms than men, particularly pruritus (p<0.05).
CONCLUSIONS: The clinical spectrum of PSC in Sweden has changed over the past 20 years; today, PSC patients are older at diagnosis and associated IBD is less frequent.

Entities:  

Mesh:

Year:  2007        PMID: 17190768     DOI: 10.1080/00365520600787994

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  7 in total

1.  Primary sclerosing cholangitis in genetically diverse populations listed for liver transplantation: unique clinical and human leukocyte antigen associations.

Authors:  Christopher L Bowlus; Chin-Shang Li; Tom H Karlsen; Benedicte A Lie; Carlo Selmi
Journal:  Liver Transpl       Date:  2010-11       Impact factor: 5.799

Review 2.  Distinctive inflammatory bowel disease phenotype in primary sclerosing cholangitis.

Authors:  A Boudewijn de Vries; Marcel Janse; Hans Blokzijl; Rinse K Weersma
Journal:  World J Gastroenterol       Date:  2015-02-14       Impact factor: 5.742

3.  Gallbladder emptying in patients with primary sclerosing cholangitis.

Authors:  Karouk Said; Nick Edsborg; Nils Albiin; Annika Bergquist
Journal:  World J Gastroenterol       Date:  2009-07-28       Impact factor: 5.742

Review 4.  Clinical features and management of primary sclerosing cholangitis.

Authors:  Marina-G Silveira; Keith-D Lindor
Journal:  World J Gastroenterol       Date:  2008-06-07       Impact factor: 5.742

5.  Malignancies in Primary Sclerosing Cholangitis--A Continuing Threat.

Authors:  Giulia Bonato; Laura Cristoferi; Mario Strazzabosco; Luca Fabris
Journal:  Dig Dis       Date:  2015-12-07       Impact factor: 2.404

Review 6.  Environmental exposure as a risk-modifying factor in liver diseases: Knowns and unknowns.

Authors:  Juliane I Beier; Gavin E Arteel
Journal:  Acta Pharm Sin B       Date:  2021-09-10       Impact factor: 11.413

7.  Investigating the safety and activity of the use of BTT1023 (Timolumab), in the treatment of patients with primary sclerosing cholangitis (BUTEO): A single-arm, two-stage, open-label, multi-centre, phase II clinical trial protocol.

Authors:  Katherine Arndtz; Margaret Corrigan; Anna Rowe; Amanda Kirkham; Darren Barton; Richard P Fox; Laura Llewellyn; Amrita Athwal; Manpreet Wilkhu; Yung-Yi Chen; Chris Weston; Amisha Desai; David H Adams; Gideon M Hirschfield
Journal:  BMJ Open       Date:  2017-07-03       Impact factor: 2.692

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.